Enterobacteriaceae are important pathogens in clinical practice no matter in the community or the hospital. As the clinical usage of antibiotics, rapid emergence of multidrug-resistant Enterobacteriaceae is noted recently. In the past two decades, extended-spectrum beta-lactamase (ESBL) caused the most clinical concerns because these enzymes would hydrolyze all beta-lactams except carbapenems and cephamycins. Therefore, carbapenems are the most important agents to treat infection caused by ESBL-producing Enterobacteriaceae. However, carbapenem-resistant Enterobacteriaceae (CRE) emerges soon after increased consumption of carbapenems. Because of extensive resistance and limit in treatment choice, CRE arouses more clinical concerns than ESBL-producing Enterobacteriaceae. In addition, some of the resistant genes of CRE are located in the plasmid that could be transmitted to other bacteria. This might result in rapid spread of carbapenem resistance. Thus, to control spreading of CRE is an important clinical issue. As the characteristics of Enterobacteriaceae, intervention strategy should be conducted in both community and healthcare settings to prevent spread of CRE.